LDL cholesterol (mmol/L), change from baseline · overweight and obese participants without T2DM (weight‐reducing phase only)
1 finding from 1 review
Constipation · overweight and obese participants without T2DM (weight‐reducing phase only)
It is very uncertain whether summary of findings table ‐ Low‐carbohydrate weight‐reducing diets changes constipation at 3 to < 12 months compared with balanced‐carbohydrate weight‐reducing diets (very low certainty).
1 finding from 1 review
Length of hospital stay · infants with bronchiolitis
1 finding from 1 review
Adverse events · infants with bronchiolitis
Summary of findings table ‐ High‐flow nasal cannula showed no clear difference in adverse events compared with standard oxygen therapy (low‐flow) (low certainty).
1 finding from 1 review
Change in respiratory rate at 20 minutes · infants with bronchiolitis
1 finding from 1 review
Change** in heart rate (beats/min) · infants with bronchiolitis
1 finding from 1 review
Need for treatment escalation · infants with bronchiolitis
Summary of findings table ‐ High‐flow nasal cannula probably leads to lower need for treatment escalation compared with standard oxygen therapy (low‐flow) (moderate certainty).
1 finding from 1 review
Duration of oxygen therapy (hours) · infants with bronchiolitis
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (selenium) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Length of hospital stay · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
Summary of findings table ‐ High flow nasal cannula (HFNC) may leads to lower treatment failure compared with low flow nasal cannula (LFNC) (low certainty).
1 finding from 1 review
Pain VAS Scale 0‐10 · patients with chronic LBP
1 finding from 1 review
Arhus Index Scale 0‐130 Pain VAS Scale 0‐10 · patients with chronic LBP
1 finding from 1 review
Motor outcome at school age (Griffiths Locomotor, MABC) · preterm infants
2 findings from 1 review
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes treatment failure compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review